Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Rev Rheumatol. Author manuscript; available in PMC 2012 September 9.
Published in final edited form as:
PMCID: PMC3437254

Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases


Programmed Cell Death (PCD) is a key process regulating immune cell development and peripheral immune homeostasis. Caspase-dependent apoptosis as well as a number of alternative cell death mechanisms account for immune cell PCD induced by cell-intrinsic as well as extrinsic pathways. In animal models, compelling evidence has emerged that genetic defects in programmed cell death can result in autoimmune disease. Autoimmune disease can arise from single-gene mutations affecting PCD, and defective PCD has been observed in some tissues and cells from patients with rheumatic disease. Selectively inducing PCD in autoreactive B and T cells is very attractive as a therapeutic strategy because it offers the possibility of permanently eliminating these cells. In addition, the anti-inflammatory effects of apoptotic cells may add to the therapeutic benefit of inducing apoptosis. Immune cell subsets vary widely in their sensitivity to specific inducers of cell death, and understanding these differences is key to predicting the outcome of inducing apoptosis for therapeutic means. Here we review approaches that have been taken to induce programmed cell death in the therapy of autoimmune disease and prospects for bringing these experimental strategies into clinical practice.

Multicellular organisms use programmed cell death to eliminate excess cells during development and maintain tissue homeostasis. Programmed cell death (PCD) occurs through a number of different mechanisms, the best understood of which is caspase-dependent apoptosis that can be triggered by extrinsic or intrinsic stimuli. Apoptotic programmed cell death can eliminate autoreactive lymphocytes both during development and in the peripheral immune system, and in general apoptotic cells do not trigger inflammation or may actively suppress it. Utilizing this mechanism to eliminate autoreactive lymphocytes in autoimmune disease is an attractive strategy for immunotherapy because of the potentially long-lasting effects of the physical removal of pathogenic cells. Here we will review the major mechanisms of programmed cell death, their disruption in immunological and rheumatological diseases, and prospects for harnessing PCD for therapeutic purposes.

Mechanisms of Programmed Cell Death and the Immune System

Apoptosis can be triggered by extrinsic signals transduced through cell surface receptors, or cell-intrinsic pathways resulting from DNA damage or other cellular stresses. These pathways are integrated by mitochondria, and converge with the activation of caspases, cysteine proteases that cleave a multitude of cellular substrates that produce the cellular changes associated with apoptosis such as DNA fragmentation, dismantling of the cytoskeleton and nuclear envelope, and packaging of cellular contents into apoptotic blebs. Apoptotic cells also display specific surface markers such as phosphatidylserine that are recognized by phagocytic cells and usually rapidly removed from the circulation. In the immune system, the extrinsic cell death pathway is mediated principally by TNF family cytokines, in particular Fas Ligand and TRAIL (TNF-Related Apoptosis Inducing Ligand). Activated T cells can produce both TRAIL and Fas Ligand after stimulation through the TCR. FasL is also reported to be constitutively expressed in some tissues associated with immune privilege such as the eyes and testis, 1,2. Myeloid cells can produce TRAIL, particularly after stimulation with type I interferons or viral infection 3. Fas (also known as CD95 or TNFRSF6) and the two functional receptors for TRAIL, DR4 and DR5, can efficiently induce apoptosis due to a conserved domain called the ‘death domain’ found in the intracytoplasmic tail of these receptors. Fas and TRAIL receptor death domains interact with the death domain in the adapter protein FADD (Fas associated death domain). A related domain, termed the Death Effector Domain (DED) in FADD recruits the cysteine protease caspase-8 receptor signaling complex. Caspase-8 is part of the caspase subfamily of cysteine proteases that cleave substrate proteins at Aspartate residues. Caspases can be involved in both inflammatory and apoptotic signaling 4.

Caspase-8 is present in the cell as a pro-enzyme that requires aggregation and cleavage in the multimerized complex consisting of ligated receptor and FADD to become fully active. This multimerized complex is termed the death inducing signaling complex (DISC)5l,6. c-FLIP, an enzymatically inactive homologue of caspase-8, is required in low amounts for processing of caspase-8 in the DISC but can block caspase-8 activation when present in larger amounts 79. The active fragments of caspase-8 assemble into a tetramer and dissociate from the receptor complex, enabling activation of downstream cytoplasmic “effector” caspases, caspase-3, -6 and -7 4. Effector caspases can cleave cellular substrates to carry out the apoptotic program. Tumor cell lines fall into two subtypes, depending on the ability of caspase-8 activated in the DISC to initiate caspase-3 cleavage directly 10,11. In cells termed ‘type I’, large amounts of caspase-8 are produced by the receptor signaling complex that can directly cleave effector caspases, whereas in other cells, termed ‘type II’, the caspase-8 generated by the DISC requires amplification by the mitochondrial mechanisms shared with the intrinsic cell death pathway (Figure 1).

Figure 1
A. Pathways of Apoptosis - Induction of apoptosis by the extrinsic pathway depends on the FADD/Caspase-8 DISC formed by the death receptor (Fas/TRAIL/TNFR1). Active caspase-8 generated from an efficient DISC, which can be inhibited by high levels of c-FLIP, ...

Fas and TRAIL receptors are both expressed on activated T cells. However, Fas-Fas Ligand interactions are principally responsible for eliminating chronically stimulated lymphocytes and maintenance of peripheral immunological tolerance 1214. More recently, Fas has been shown to trigger non-apoptotic responses such as increased migration, chiefly in myeloid cells 14, Chen, 2010 #9692,15. TRAIL can induce rapid cell death in transformed tumor cells, but its physiological function is less clear. Experiments with TRAIL deficient and TRAIL-R deficient mice have revealed roles in tumor surveillance and elimination of CD8+ T cells which have not received T cell help from CD4+ T cells 16,17. Two other members of the TNF superfamily, TNFR1 and DR3, interact with the adapter protein TRADD, which mediates assembly of a primary signaling complex containing TRAF (TNF-receptor associated factors), Inhibitor of Apoptosis (IAP) proteins 1 and 2 and the RIP1 (Receptor Interacting Protein 1). This protein complex triggers pro-inflammatory cellular responses through NF-kB and MAP-kinase signaling 18. Not until hours after receptor internalization and dissociation of TRADD from the receptor are FADD and caspase-8 recruited to this signaling complex (termed complex II)18, allowing apoptosis induction to occur. The regulatory protein c-FLIP is synthesized in response to NF-kB activation and is responsible for at least part of the protective functions of NF-kB. Thus, except in circumstances where NF-kB activation is blocked, stimulation of TNFR1 and DR3 usually result in cellular activation and synthesis of pro-inflammatory cytokines and do not induce PCD. Other members of the TNF-receptor family do not have a death domain and cannot directly induce cell death. Instead they recruit TRAF proteins via peptide consensus sequences, triggering production of pro-inflammatory cytokines and cell survival. However, these receptors can trigger cell death indirectly, through modulating the availability of signaling proteins available to apoptosis-inducing receptors. For example, signaling by the TNF-family member TWEAK results in the recruitment and subsequent degradation of the TRAF2 and IAP-1. 19 Depletion of these proteins in the TNFR1 signaling complex enhances the apoptosis-inducing ability of TNFR1 20. Such cross talk might be harnessed for therapeutic purposes.

Cell-intrinsic stimuli can trigger apoptosis through activation of caspases independently of surface receptors (Figure 1). Intrinsic stimuli include withdrawal of cytokines that support cell survival, exposure to mutagens resulting in DNA damage, or hormones such as glucocorticoids 21,22. Sensors of DNA damage or hormone receptors relay apoptotic signals through the Bcl-2 family of proteins comprising of pro-apoptotic and anti-apoptotic members characterized by the presence of the BH (Bcl-2 homology) domains. The anti-apoptotic proteins Bim, Bid, Noxa and Puma contain only BH3 domains, however, Bax, Bak are multi-BH domain members. Bid can be cleaved by active caspase-8 in the signaling complex of death receptors, resulting in a truncated protein (tBid). tBid translocates to the mitochondria where it induces conformational changes in other bcl-2 family member proteins, resulting a rapid opening of channels in the mitochondrial outer membrane, referred to as Mitochondrial Outer Membrane Permeability transition (MOMP). MOMP disrupts mitochondrial energy generation and releases cytochrome-c into the cytoplasm, which is a key activator of the ‘apoptosome’ a complex of caspase-9 and the APAF-1 protein. The anti-apoptotic members (Bcl-2, Bcl-XL, Mcl-1) contain multiple BH domains that play a critical role in directly inhibiting pro-apoptotic Bcl-2 members through a conformational interaction. A second layer of regulation is mediated by inhibitor of apoptosis (IAP) proteins such as XIAP (X-linked IAP), which bind to and inhibit the active form of effector caspases. Molecules such as SMAC/diablo that are also released from the mitochondria after MOMP can inactivate IAP proteins, providing an additional feed-forward loop that reinforces caspase activation. Together, these regulatory pathways result in a latent period in which upstream signals such as death receptor ligation produce small amounts of caspase activity and activate upstream BH3 proteins, followed by a very rapid (2–3 minute) onset of apoptosis with MOMP, release of cytochrome c, and effector caspase activation occurring almost simultaneously 23 (Figure 1).

Intrinsic and extrinsic apoptosis pathways come into play during different phases of the immune response. After the rapid proliferation of antigen-specific T cells that occurs during the first four to seven days of an acute immune response, the contraction of effector T cells is largely due to cytokine withdrawal via the intrinsic apoptotic pathway. Once the T cell pool expands beyond the availability of IL-7 and IL-15, levels of Bcl-2 fall, levels of the pro-apoptotic BH3 protein Bim rise, and apoptosis mediated by Bim ensues 24,25. Fas comes into play in the elimination of T cells only under conditions of chronic infection or repetitive stimulation by autoantigens. 2628

Repeated T cell receptor (TCR) stimulation upregulates FasL, which induces apoptosis in Fas-bearing T cells through the process of restimulation induced cell death (RICD). RICD leads to clonal deletion of these cells without affecting bystander antigen non-specific T cells, even if they also express Fas 29. This specificity occurs because TCR stimulation induces a ‘competency to die’ signal in addition to FasL synthesis. This TCR specific signal preferentially sensitizes restimulated T cells to die in comparison to bystander activated T cells. Not all aspects of TCR signaling are necessary to sensitize T cells to Fas-dependent apoptosis, but activation of Rac GTPases, members of the small G protein signaling family that regulate actin polymerization and cytoskeletal remodeling have been shown to be necessary 30. One of the results of Rac activation is translocation of Fas to lipid raft microdomains, which increase the efficiency of Fas-induced apoptosis 30,31. How this type of cytoskeletal reorganization relates to changes that take place during formation of an immune synapse between a T cell and an antigen-presenting cell is not known.

Caspase-independent cell death mechanisms

Use of caspase inhibitors and caspase deficient mice have identified several mechanisms of caspase-independent cell death (CICD) 32. Necrosis and autophagic cell death are two such caspase-independent mechanisms 33. Necrosis, previously considered to be an uncontrolled catastrophic form of cell death, has been found resulting in some cases from regulated signaling events. Necrosis resulting from caspase inhibition during death receptor signaling is termed necroptosis, and is morphologically indistinguishable from necrosis. This ‘backup’ mechanism of cell death may constitute an immune defense mechanism against viruses, which often encode caspase inhibitors in their genome. Recent evidence has implicated RIP1 and RIP3, proteins also involved in TNF receptor induced NF-kB activation, in necroptosis 34. Small molecule inhibitors of the RIP1 protein kinase termed necrostatins can block necroptosis in some cell types. 35. Autophagy, on the other hand, is a physiological response to nutrient deprivation in which intracytoplasmic organelles are recycled in double walled membrane bound vacuoles termed autophagosomes. Autophagic cell death is characterized by accumulation of autophagic vacuoles in cells undergoing cell death, and can be blocked by inhibition of autophagy, suggesting that autophagy may be part of the mechanism of this type of cell death 36. Recently, autophagic cell death has been suggested to underlie the cell death that occurs when T cells are activated in the presence of caspase inhibitors or genetic deficiency of FADD or Caspase-8 37. These findings suggest that caspases may play a critical role controlling lymphocyte survival at both ends of a spectrum: too little caspase activation triggers an autophagic death program, whereas high levels of caspase activation, such as after ligation of Fas, triggers apoptotic cell death.

Life after cell death – recognition and uptake of apoptotic cells

Apoptotic cells are usually rapidly phagocytosed by macrophages. The process of phagocyte recognition and engulfment depends on various recognition signals that are exhibited by the cell undergoing apoptosis. One of the classical recognition signals is the membrane lipid phophatidylserine (PS), which translocates from the inner to outer leaflet of the plasma membrane upon apoptosis. PS can be recognized by specific receptors on phagocytes, but the efficiency of apoptotic cell recognition is increased by many other intermediary molecules that aid in the recognition of dying cells 38.

After ingesting apoptotic cells, macrophages downregulate secretion of pro-inflammatory cytokines such as TNF, IL-8 and IL-1b and increase production of anti-inflammatory mediators such as TGF-b 39. After ingestion of apoptotic cells dendritic cells produce TGF-b, and induce naïve T cells to differentiate into regulatory cells 40. Because of these responses, uptake of apoptotic cells has been generally thought to suppress inflammation and promote adaptive immune tolerance.

The tolerogenic nature of apoptotic cell recognition and uptake is underscored by the autoimmunity that results from genetic lesions in the recognition and uptake of apoptotic cells. The classical complement component C1q is required for efficient apoptotic cell phagocytosis and binds to the C1q receptor on phagocytes. C1q knockout mice develop glomerulonephritis, accumulate apoptotic bodies and exhibit increased mortality 41 Humans with homozygous C1q deficiency also have a strong predisposition to develop SLE 42. Mice lacking other components of complement, receptors in the axl/tyro3/mer family that indirectly recognize PS through intermediary bridge molecules, or Milk fat globule epidermal growth factor-8 (MFG-E8), a bridging molecule in apoptotic cell recognition, also develop systemic autoimmunity 4345. Taken together these results suggest that coordinated recognition and uptake of apoptotic cells is an important part of immunological self- tolerance. The role of this process in controlling autoimmunity in the setting of spontaneous disease not associated with genetic deficiencies in complement or apoptotic uptake mechanisms remains to be elucidated.

Genetic diseases involving apoptosis and evidence for altered apoptosis in more common rheumatic diseases

The central role of the Fas-FasL system in maintaining peripheral tolerance is exemplified by the autoimmune syndromes that result from genetic defects in Fas or Fas Ligand. Mice harboring loss of function mutations in Fas (lpr, lymphoproliferation), or Fas Ligand (gld, generalized lymphadenopathy) develop massive lymphadenopathy, splenomegaly, anti-DNA antibodies and high levels of serum IgG and IgM. Mice on the MRL background succumb to lethal inflammatory arthritis and nephritis by 5 months of age 46. One characteristic feature of impaired T cell apoptosis is the accumulation of large numbers of abnormal αβTCR+ CD4CD8 (double-negative or DN) T cells. Lineage specific deletion of Fas in T cells, B cells or antigen presenting cells all result in varying degrees of autoimmune manifestations in mice, indicating an essential role of Fas expression in all three cell types for maintaining peripheral immune tolerance 47. In humans, dominant negative mutations in Fas or Fas Ligand cause the familial autosomal dominant Autoimmune Lymphoproliferative Syndrome (ALPS), which bears a striking resemblance to Fas deficiency in mice. ALPS typically presents in childhood with chronic lymphadenopathy, hepatosplenomegaly, and autoimmunity, most commonly manifested as autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura. DN T cells accumulate in the peripheral blood and to an even greater extent in lymph nodes in ALPS 4850. Mutations throughout the Fas protein have been documented in ALPS patients, with the most common being mutations in the death domain that impair formation of the Fas signaling complex. Interestingly patients with caspase-8 deficiency present with immunodeficiency rather than autoimmunity and have defects in lymphocyte activation 51, perhaps due to the role of caspases in preventing autophagic cell death during lymphocyte activation as discussed above.

In the more common rheumatic diseases, multiple genetic susceptibility loci interact with the environment to produce disease. Although no single genetic locus controls disease, a number of candidate genetic variants may influence cellular susceptibility to apoptosis. Phenotypic studies have found alterations in apoptosis or apoptotic cell uptake in tissue samples from patients with rheumatic diseases. In Rheumatoid Arthritis (RA), the accumulation of inflammatory cells at sites of active disease could be due to increased cellular proliferation or reduced apoptosis. Experiments using a number of different detection techniques have yielded remarkably few apoptotic cells in rheumatoid synovium 52. While peripheral monocytes express Fas/FasL and are highly sensitive to Fas apoptosis, synovial macrophages obtained from diseased joints have increased expression of c-FLIP and are resistant to apoptosis induced by Fas. Reduction in c-FLIP can restore Fas sensitivity, suggesting that reducing c-FLIP expression through RNA interference of blockade of NF-kB activity may be a therapeutic strategy to reduce macrophage numbers in RA 53. Inhibition of NF-kB activity can also sensitize macrophages to undergo apoptosis in response to TNF 54, suggesting therapeutic NF-kB inhibition as another strategy to subvert the effects of TNF in RA.

In SLE, alterations in the kinetics of cell death and uptake of apoptotic cells may alter the normal non-immunogenic nature of apoptosis. T lymphocytes in SLE have been observed to undergo reduced apoptosis when stimulated through the TCR 55. This may be due to alterations in TCR signaling proteins, including deficiency in the TCR zeta chain, which is known to be required for TCR-induced apoptosis 56. However, T cells from patients with SLE have also been found to undergo accelerated spontaneous apoptosis 57. However, some of these findings may be due to alterations in T cell subsets or activation status known to occur in SLE, rather than cell-intrinsic differences in apoptotic signaling. Another line of evidence has revealed altered uptake of apoptotic cells as a possible pathogenic mechanism in SLE. Macrophages derived from SLE patient monocytes are impaired in their ability to uptake apoptotic material in vitro 58. In vivo, lymph node biopsies from SLE patients with active disease contained multiple non-phagocytosed apoptotic cells in the germinal centers, compared to none in control biopsies 58. TUNEL assays have demonstrated attachment of apoptotic materials to follicular dendritic cells in SLE patients, allowing these antigens to ultimately be presented to T cells5860. Accumulation of apoptotic cells in SLE may allow autoantigens that are normally eliminated through phagocytosis to become immunogenic, adding ‘fuel to the fire’ of autoimmunity in SLE and other autoimmune diseases 61.

Induction of programmed cell death by current and potential future therapies for rheumatic diseases

A number of therapeutic agents already in use for rheumatic disease induce apoptosis as all or part of their mode of action. Rituximab, a chimeric anti-CD20 B cell-specific monoclonal antibody that was originally developed to treat B cell malignancies, is approved for use in RA, and is used in other B-cell dependent autoimmune diseases, including pemphigous and SLE. Rituximab profoundly depletes circulating B cells through a number of mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis 62,63. Some studies have suggested that anti-TNF monoclonal antibodies (but not TNFR2-Fc fusion proteins such as etanercept) can acutely induce apoptosis in T cells and synovial macrophages that express surface TNF by similar mechanisms 64. This may explain the superior efficacy of anti-TNF agents over etanercept in diseases such as inflammatory bowel disease. ADCC has been exploited in newer investigational agents to target specific populations of cells, such as an anti-lymphotoxin-β mAb that specifically depletes Th1 and Th17 T cells based on their increased expression of surface lymphotoxin 65.

Small molecule therapeutics currently used in the management of rheumatic diseases may also exert some of their therapeutic effects through apoptosis. High dose glucocorticoids induce apoptosis in eosinophils and lymphocytes. The mechanisms by which this occur are complex, likely involving repression of transcription factors that promote cellular survival such as NF-kB, and activation of caspase-dependent apoptosis 66. Among other mechanisms, methotrexate, a mainstay of therapy for RA, may act through induction of programmed cell death. In vitro, methotrexate (MTX) can induce apoptosis in 20–30% of activated T cells 67,68 at concentrations comparable to peak plasma levels in patients on methotrexate for RA. Generation of reactive oxygen species and loss of mitochondrial membrane potential has been implicated in MTX-induced cell death, and MTX has also been reported to potentiate Fas-induced apoptosis 67,68. Some support for the idea that MTX may deplete activated T cells came from a study in which MTX depleted a subset of activated CD4+CD28+ T cells that accumulate in RA patients 69. Cyclophosphamide can also induce apoptosis in activated T cells 67, and some of its beneficial effects in SLE and vasculidites may stem from elimination of autoreactive lymphocytes.

Rational targeting of the intrinsic cell death pathway by manipulating the Bcl-2 family of proteins can induce apoptosis and may be useful in the treatment of rheumatic diseases. A phosphorothioate antisense oligonucleotide (Oblimersen sodium) targeting Bcl-2 has shown modest effects on progression and survival in patients with chronic lymphocytic leukemia and malignant melanoma 70. ABT-737 and other small molecule drugs have been developed that mimic the activity of BH3 peptides to bind and inactivate Bcl-2. These drugs can potently induce apoptosis in tumor cells, although phosphorylated Bcl-2 and other anti-apoptotic Bcl-2 family proteins such as Mcl-1 are resistant to the effects of ABT-737 7173. ABT-737 was recently shown to be efficacious in mouse models of arthritis and immune complex nephritis, although significant depression of B and T cell responses were seen, suggesting that the use of this agent may result in some generalized immunosuppression 74.

Targeting Fas and other death receptors in rheumatic diseases

Because of its intrinsic ability to induce apoptosis and the heightened sensitivity of restimulated T cells to Fas-induced apoptosis, engagement of the TNF-receptor Fas could be an interesting therapeutic strategy to eliminate autoreactive T cells without knowing their antigenic specificity. Overexpression of the FADD adapter protein in cultured RA synoviocytes induced apoptosis in these cells, and in a xenograft mouse model of proliferating rheumatoid synovium, ectopic expression of FADD through retroviral transduction lead to a significant reduction of synoviocytes and mononuclear cells 75. Reducing levels of c-FLIP, another molecule that regulates Fas signaling has been shown to sensitize fibroblast-like synoviocytes from RA patients to Fas-induced apoptosis and sensitized T cells to TCR-induced apoptosis 76,77. Indirect targeting of Fas through its ligand is another plausible therapeutic mechanism. The forkhead transcription factor Foxo3a is an upstream inhibitor of FasL synthesis. Foxo3a deficient mice are very resistant to inflammatory arthritis in the K/BxN serum transfer model of rheumatoid arthritis due to increased neutrophil apoptosis as a result of upregulated FasL synthesis 78.

Directly inducing apoptosis through Fas is another strategy for elimination of potentially autoreactive cells. Use of Anti-Fas monoclonal antibodies in vivo has been limited by acute and fatal hepatic failure that was observed in mice due to Fas-induced hepatocyte apoptosis 79. This effect is partially dependent on Fc-receptor mediated crosslinking of the anti-Fas mAb 80. Using FasL rather than anti-Fas and targeting specific cell populations for Fas mediated apoptosis has avoided this problem in a number of experimental models. Although crosslinking of FasL with a secondary antibody reproduced the liver toxicity of anti-Fas mAb, an engineered hexameric version of Fas Ligand retains cytotoxic potential and does not induce fatal liver toxicity 81,82. Human hexameric FasL (APO010, Topotarget) is currently in early stage human trials for cancer therapy. A fusion protein containing FasL and a fibroblast activation protein (FAP)-specific single chain antibody limited the induction of apoptosis to only cells expressing FAP. This FasL-anti-FAP fusion protein inhibited the growth of a FAP-expressing tumor without the lethality seen with nonspecific Fas targeting 83. Focusing FasL on tumor cells through a fusion protein combining FasL with a high-affinity antibody against the T-cell leukemia-associated antigen CD7 lead to apoptosis of CD7-expressing cells, and moderate tumoricidal activity in CD7-expressing leukemic cells from T-ALL patients 84. Delivery of FasL has had some success in treating animal models of arthritis. A T lymphoma cell line overexpressing FasL-induced apoptosis in cultured synoviocytes from RA patients and could deplete synoviocytes and mononuclear cells in the rheumatoid synovial xenografts 85. Adenoviral vector-based delivery of FasL ameliorated joint pathology in CIA 86. These studies suggest that treating inflammatory joint disease through sensitizing synovial cells to Fas-mediated apoptosis may be a viable therapeutic strategy provided that these effects can be spatially limited to affected joints.

Better understanding of the pathways that sensitize cells to apoptosis-inducing receptors has led to therapeutic strategies to activate these pathways and allow apoptosis to be triggered by endogenous ligands. The cytoplasmic apoptosis inhibitor XIAP restrains both extrinsic and intrinsic apoptosis pathways by binding to and inhibiting active effector caspases 3 and 7. Mimetics of the N-terminal peptide in the protein SMAC, which is released from mitochondria during apoptosis, can displace XIAP from effector caspase. SMAC mimetics or reduction in XIAP levels sensitizes many cell lines to undergo apoptosis in response to TNF, TRAIL and Fas Ligand, 87,88. Reduction of XIAP levels in mice through treatment with SMAC mimetics or genetic deficiency also sensitized hepatocytes to FasL mediated apoptosis. In some tumor cell lines, SMAC mimetics initiated an autocrine loop of TNF-TNFR1 mediated cell death through activating the alternative NF-kB pathway and TNF production, but this has not been observed in primary cells. SMAC mimetics are interesting candidates for therapies aimed at increasing sensitivity to apoptosis caused by endogenous or exogenous death receptor ligands.

T cell subsets vary in their sensitivity to Fas-induced apoptosis 89, Riou, 2007 #3747 and signaling through the TCR sensitizes cells to Fas-induced apoptosis as well as inducing transcription and secretion of Fas Ligand 90 Understanding the signaling pathways through which the TCR induces apoptosis may allow therapeutic manipulation to promote apoptosis of autoreactive lymphocytes. Sensitivity to Fas-induced apoptosis can be induced by low affinity peptides for the TCR that do not induce Fas Ligand or cytokine induction, suggesting that this is mediated through distinct signaling pathways 91. TCR-mediated sensitization to Fas-mediated apoptosis requires translocation of Fas to lipid raft microdomains in a manner dependent on the Rac Family of GTPases 30,31. T cells lacking the Wiskott-Aldrich Syndrome protein (WASp), which mediates actin remodeling downstream of the TCR, have defective TCR-induced apoptosis associated with reduced secretion of Fas Ligand 92. This defect may be one factor predisposing patients with the Wiskott Aldrich Syndrome and WASp deficient mice to develop systemic autoimmunity at high frequencies in addition to the immunodeficiency associated with the Wiskott-Aldrich Syndrome. Alternative ligands that activate these signaling pathways may be one strategy to sensitize autoreactive to undergo TCR-mediated apoptosis even when the autoantigen is unknown, as is the case with many human diseases.

These findings suggest a number of therapeutic targets that may specifically sensitize T cells to undergo apoptosis when they are chronically stimulated. Agents already used in the treatment of rheumatic disease, such as cyclophosphamide, glucocorticoids or anti-TNF mAb may also exert part of their effects through inducing apoptosis. Although in diseases such as SLE apoptotic cells may become abnormally immunogenic, conventional therapies that likely induce apoptosis in vivo are more beneficial then harmful. Blockade of Interleukin-6 with tocilizumab, a mAb against IL-6R recently approved for the treatment of RA in the U.S., is one example, as interleukin-6 can protect against TCR and Fas-mediated apoptosis in a number of settings 9395. Development of these therapeutic strategies has the potential to fulfill one of the long sought goals in the therapy of autoimmune disease: eliminating autoreactive cells with minimal generalized immunosuppression.

Table 1
Therapies Targeting Apoptosis
Table 2
Potential therapies targeting the Fas/FasL apoptosis pathway

Key Points

  • Apoptosis or programmed cell death is mediated by extrinsic ‘death receptors’ or intrinsic signals triggered by responses to cellular stress. Apoptosis is essential in maintenance of immune cell numbers
  • The caspase family of intracellular proteases are the main effectors of apoptosis, but caspases also have non-apoptotic functions, and caspase-independent necrotic or autophagic cell death also occurs
  • Uptake of apoptotic cells by antigen-presenting cells promotes immunological tolerance through suppressing the ability of these cells to activate the immune system, while phagocytosis of necrotic or infected cells activates immune responses
  • Genetic mutations or variants in regulators of cell death or dead cell clearance can predispose to autoimmunity
  • A number of current therapies for autoimmune disease lead to immune cell depletion via programmed cell death
  • Better understanding of the mechanisms regulating apoptosis sensitivity of immune cells suggests new targets for therapies designed to specifically deplete autoreactive lymphocytes


This work was supported by funds from the NIAMS intramural research program. We would like to thank Eric Hanson and Michael Ombrello for critical reading of this manuscript. Min Deng is a student in the Clinical Research Training program, a joint program of the NIH and Pfizer, inc.



Madhu Ramaswamy is a Research Fellow at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and is supported by the NIAMS Intramural program. Her interest in the regulation of the TNF receptor superfamily started with her graduate studies at the University of Illinois at Chicago, where she studied mechanisms of TRAIL receptor signaling. After graduating in 2005, she moved to Richard Siegel’s lab at the Autoimmunity Branch of NIAMS, where her research focuses on studying regulatory mechanisms of Fas/FasL pathway in mediating peripheral T cell tolerance and autoimmunity.


Min Deng is a medical student at Case Western Reserve University and a fellow in the NIH’s Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc (via a grant to the Foundation for NIH from Pfizer Inc).


Richard Siegel trained as an M.D./Ph.D. student at the University of Pennsylvania School of Medicine, in Internal Medicine and clinical Rheumatology at the Hospital of the University of Pennsylvania. He then moved to NIH to do postdoctoral training in 1996, where he worked in Michael Lenardo’s laboratory in NIAID. In 2001, Dr. Siegel moved to NIAMS, and is presently a Senior Investigator in the Autoimmunity Branch in NIAMS intramural research program. His laboratory work is directed at understanding how alterations in regulatory signaling pathways lead to abnormal immune responses, chronic inflammation, and autoimmune diseases, with an emphasis on the biology of TNF-family cytokines. More about the lab can be found at


Literature search criteria: References for this article were found through searching for the keywords apoptosis, programmed cell death, autoimmune disease, rheumatic disease, and immunological tolerance. Other useful resources on apoptosis: (a web compendium of apoptosis terminologies, methods, and other links).


1. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228–238. [PubMed]
2. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189–1192. [PubMed]
3. Kirshner JR, Karpova AY, Kops M, Howley PM. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol. 2005;79:9320–9324. [PMC free article] [PubMed]
4. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol. 2006;6:308–317. [PubMed]
5. Kischkel FC, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO Journal. 1995;14:5579–5588. [PubMed]
6. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26–35. [PubMed]
7. Micheau O. The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex. J Biol Chem. 2002;277:45162–45171. [PubMed]
8. Zhang N, He YW. An essential role for c-FLIP in the efficient development of mature T lymphocytes. J Exp Med. 2005 [PMC free article] [PubMed]
9. Budd R, Yeh W, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006;6:196–204. [PubMed]
10. Scaffidi C, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675. [PubMed]
11. Shell S, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007;104:11400–11405. [PubMed]
12. Ramaswamy M, Siegel RM. A FAScinating Receptor in Self-Tolerance. Immunity. 2007;26:545–547. [PubMed]
13. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1:469–474. [PubMed]
14. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180–192. [PMC free article] [PubMed]
15. Letellier E, et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity. 2010;32:240–252. [PubMed]
16. Janssen EM, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88–93. [PubMed]
17. Takeda K, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195:161–169. [PMC free article] [PubMed]
18. Micheau O. Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes. Cell. 2003;114:181–190. [PubMed]
19. Vince JE, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol. 2008;182 [PMC free article] [PubMed]
20. Ashwell JD. TWEAKing death. J Cell Biol. 2008;182:15–17. [PMC free article] [PubMed]
21. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255–260. [PubMed]
22. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol. 2003;21:71–105. [PubMed]
23. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626–629. [PubMed]
24. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol. 2002;14:354–359. [PubMed]
25. Bouillet P, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286:1735–1738. [PubMed]
26. Weant AE, et al. Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity. 2008;28:218–230. [PubMed]
27. Hutcheson J, et al. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity. 2008;28:206–217. [PubMed]
28. Hughes PD, et al. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 2008;28:197–205. [PMC free article] [PubMed]
29. Hornung F, Zheng L, Lenardo MJ. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol. 1997;159:3816–3822. [PubMed]
30. Ramaswamy M, et al. Cutting edge: Rac GTPases sensitize activated T cells to die via Fas. J Immunol. 2007;179:6384–6388. [PubMed]
31. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol. 2004;5:182–189. [PubMed]
32. Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE. 2006;2006 [PubMed]
33. Kroemer G, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3–11. [PMC free article] [PubMed]
34. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138:229–232. [PubMed]
35. Degterev A, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313–321. [PubMed]
36. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008;9:1004–1010. [PMC free article] [PubMed]
37. Bell BD, et al. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci U S A. 2008;105:16677–16682. [PubMed]
38. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9:353–363. [PMC free article] [PubMed]
39. Fadok VA, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890–898. [PMC free article] [PubMed]
40. Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation SUPPLEMENT. Nature. 2009;458:78–82. doi: 10.1038/nature07781. [PubMed] [Cross Ref]
41. Botto M, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998;19:56–59. [PubMed]
42. Bowness P, et al. Hereditary C1q deficiency and systemic lupus erythematosus. QJM. 1994;87:455–464. [PubMed]
43. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001;293:306–311. [PubMed]
44. Hanayama R, et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science. 2004;304:1147–1150. [PubMed]
45. Cook HT, Botto M. Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2:330–337. [PubMed]
46. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9:243–269. [PubMed]
47. Stranges PB, et al. Elimination of antigen-presenting cells and autoreactive T cells by fas contributes to prevention of autoimmunity. Immunity. 2007;26:629–641. [PMC free article] [PubMed]
48. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. 1999;130:591–601. [PubMed]
49. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643–1649. [PubMed]
50. Fisher GH, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–946. [PubMed]
51. Chun HJ, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395–399. [PubMed]
52. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol. 2002;2:527–535. [PubMed]
53. Perlman H, et al. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med. 1999;190:1679–1688. [PMC free article] [PubMed]
54. Liu H, et al. TNF-alpha-induced apoptosis of macrophages following inhibition of NF-kappa B: a central role for disruption of mitochondria. J Immunol. 2004;172:1907–1915. [PubMed]
55. Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol. 1996;81:293–302. [PubMed]
56. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest. 1998;101:1448–1457. [PMC free article] [PubMed]
57. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994;152:3685–3692. [PubMed]
58. Baumann I, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46:191–201. [PubMed]
59. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol. 1997;158:4525–4528. [PubMed]
60. Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol. 2000;74:61–88. [PubMed]
61. Viorritto IC, Nikolov NP, Siegel RM. Autoimmunity versus tolerance: can dying cells tip the balance? Clin Immunol. 2007;122:125–134. [PMC free article] [PubMed]
62. Mouquet H, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128:2859–2869. [PubMed]
63. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 2008;13:954–966. [PubMed]
64. Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol. 2007;3:227–233. [PubMed]
65. Chiang EY, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15:766–773. [PubMed]
66. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9:6–19. [PubMed]
67. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255–266. [PubMed]
68. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res. 2005;54:273–280. [PubMed]
69. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunol Invest. 2004;33:351–362. [PubMed]
70. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol. 2009;21:516–523. [PubMed]
71. Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681. [PubMed]
72. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375–388. [PubMed]
73. van Delft MF, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389–399. [PMC free article] [PubMed]
74. Bardwell PD, et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009;182:7482–7489. [PubMed]
75. Kobayashi T, et al. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes. Gene Ther. 2000;7:527–533. [PubMed]
76. Palao G, et al. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis Rheum. 2004;50:2803–2810. [PubMed]
77. Mourich DV, et al. Antisense targeting of cFLIP sensitizes activated T cells to undergo apoptosis and desensitizes responses to contact dermatitis. J Invest Dermatol. 2009;129:1945–1953. [PubMed]
78. Jonsson H, Allen P, Peng SL. Inflammatory arthritis requires Foxo3a to prevent Fas ligand–induced neutrophil apoptosis. Nat Med. 2005;11:666–671. [PubMed]
79. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449–1456. [PubMed]
80. Xu Y, et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 2003;171:562–568. [PubMed]
81. Schneider P, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205–1213. [PMC free article] [PubMed]
82. Holler N, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428–1440. [PMC free article] [PubMed]
83. Samel D, et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem. 2003;278:32077–32082. [PubMed]
84. Bremer E, ten Cate B, Samplonius DF, de Leij LF, Helfrich W. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood. 2006;107:2863–2870. [PubMed]
85. Okamoto K, et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther. 1998;5:331–338. [PubMed]
86. Zhang H, et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest. 1997;100:1951–1957. [PMC free article] [PubMed]
87. Varfolomeev E, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem. 2009;284:34553–34560. [PubMed]
88. Varfolomeev E, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–681. [PubMed]
89. Ramaswamy MC, Cleland AC, Deng SY, Price M, Rao S, Siegel KV, RM Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains. Cell Death Differ. 2010 In press. [PMC free article] [PubMed]
90. Ramaswamy M, Cleland SY, Cruz AC, Siegel RM. Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses. Results Probl Cell Differ. 2009;49:17–47. [PMC free article] [PubMed]
91. Combadiere B, e Sousa CR, Germain RN, Lenardo MJ. Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands. J Exp Med. 1998;187:349–355. [PMC free article] [PubMed]
92. Nikolov NP, et al. Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein. Blood. 2010 [PubMed]
93. Ayroldi E, et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death. Blood. 1998;92:4212–4219. [PubMed]
94. Haga S, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest. 2003;112:989–998. [PMC free article] [PubMed]
95. Kovalovich K, et al. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem. 2001;276:26605–26613. [PubMed]